Literature DB >> 125923

Chelation therapy in lead nephropathy.

J M Morgan.   

Abstract

Although treatment has been well defined for childhood lead poisoning and for industrial lead exposure, the treatment of lead nephropathy has been poorly studied. The available chelating agents are reviewed and the results of treatment in 17 cases of lead nephropathy are shown. It is concluded that lead nephropathy should be recognized early and treated energetically, as this may stabilize or improve renal function. Since EDTA is excreted much like creatinine, the dosage must be reduced proportionately in response to elevated serum creatinine levels in the patient with renal failure.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 125923     DOI: 10.1097/00007611-197508000-00015

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  2 in total

1.  Chelation therapy and the tissue distribution and excretion of lead in mice.

Authors:  E M Sorensen; E S Moretti; A Lindenbaum
Journal:  Arch Environ Contam Toxicol       Date:  1980       Impact factor: 2.804

Review 2.  Chronic low-level lead exposure. Its role in the pathogenesis of hypertension.

Authors:  D S Sharp; C E Becker; A H Smith
Journal:  Med Toxicol       Date:  1987 May-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.